<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Despite being widely reported in patients with <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, vena cava superior (VCS) syndrome linked to <z:mp ids='MP_0005048'>thrombosis</z:mp> is a major catheter complication that can be encountered during the use of the hemodialysis catheter </plain></SENT>
<SENT sid="1" pm="."><plain>Antithrombin III (AT-III), responsible for a large part of thrombin inactivation capacity in plasma, is the most powerful inhibitor of the <z:mp ids='MP_0005048'>thrombosis</z:mp> process </plain></SENT>
<SENT sid="2" pm="."><plain>This report describes a case of VCS syndrome developing two weeks following the extraction of a right-sided subclavian catheter in a patient transferred from peritoneal dialysis to hemodialysis for one week due to leakage </plain></SENT>
<SENT sid="3" pm="."><plain>The patient presented complaining of swelling and pain in the right arm </plain></SENT>
<SENT sid="4" pm="."><plain>At Doppler examination, total <z:mp ids='MP_0005048'>thrombosis</z:mp> was observed in the subclavian and internal jugular vein </plain></SENT>
<SENT sid="5" pm="."><plain>At advanced examinations due to lack of response to <z:chebi fb="5" ids="28304">heparin</z:chebi> and clinical worsening, VCS and AT-III deficiency were determined </plain></SENT>
<SENT sid="6" pm="."><plain>Following thrombolytic therapy with streptokinase, AT-III levels were raised by the administration of plasma, and clinical and radiological stabilization was established by continuing <z:chebi fb="5" ids="28304">heparin</z:chebi> and continuous oral <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy </plain></SENT>
</text></document>